At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
HKI-272drug
Likely dose
HKI-272 320mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating HKI-272 for Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. Completed, enrolled 172 participants across 19 sites in 5 countries.
Detailed Summary
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung, Lung Neoplasms
CountriesFrance, Hungary, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedDec 2005
Primary CompletionJan 2009
TodayJul 2026
First PostedDec 19, 2005
Enrollment StartDec 1, 2005
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.5 years ago
Interventions
HKI-272drug
320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.